医学
胰岛素瘤
连续血糖监测
糖尿病
胰岛素
可靠性(半导体)
低血糖
血糖自我监测
胰岛素泵
内科学
2型糖尿病
急诊医学
临床试验
1型糖尿病
重症监护医学
内分泌学
作者
Lukas van Baal,Lorenz Raess,Annie Mathew,Lahner Harald,Nicole Unger,Dagmar Führer
摘要
Abstract Aims Glucose monitoring is increasingly based on continuous glucose monitoring (CGM) systems. However, data on the accuracy of CGM within the hypoglycaemic range is sparse. This study investigated CGM accuracy within the hypoglycaemic range in three different clinical settings of hypoglycaemia. Materials and Methods Ninety‐two people with various causes of hypoglycaemia were analysed: (i) people during insulin tolerance testing (ITT) ( n = 63); (ii) people with insulinoma ( n = 16); and (iii) people with diabetes receiving subcutaneous insulin therapy ( n = 13). CGM accuracy was evaluated for subgroups and different glucose rates of change (RoC) using mean absolute relative difference (MARD), percentage of glucose values within ±20 mg/dL of point‐of‐care glucose (%20/20), diabetes technology society error grid and Bland–Altman analysis (BAA). Results Four hundred sixty‐four CGM/POC glucose pairs were obtained (39.7% level 1, 60.3% level 2 hypoglycaemia). CGM accuracy decreased from people with diabetes receiving subcutaneous insulin therapy (MARD: 13.9%; %20/20: 81.5%) to those with ITT (MARD: 50.8%; p < 0.01, %20/20: 67.5%; p .02). CGM accuracy significantly decreased with higher RoC. Proportion of CGM values with moderate risk in failing to detect potentially dangerous hypoglycaemia increased from people with diabetes (1.5%) and insulinoma (1.2%) to people with ITT (14.2%, p < 0.01). BAA revealed a significantly increasing bias of −3.3 + 10.7 mg/dL in people with diabetes receiving insulin therapy to −15.2 ± 13.6 mg/dL in people with ITT ( p < 0.01). Conclusion CGM accuracy can vary in different clinical hypoglycaemia scenarios. While it remains acceptable in people with diabetes receiving subcutaneous insulin therapy and people with insulinoma, it appears to be inaccurate for glucose monitoring during ITT.
科研通智能强力驱动
Strongly Powered by AbleSci AI